C4 Therapeutics, or C4T, announced that the FDA has cleared the company’s investigational new drug, or IND, application for CFT8919, an orally bioavailable BiDAC degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer, or NSCLC, patients. This milestone marks C4T’s fourth IND clearance from its proprietary TORPEDO platform. In May 2023, C4T and Betta Pharmaceuticals entered into an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China, including Hong Kong SAR, Macau SAR and Taiwan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CCCC:
- C4 Therapeutics Explodes Higher on Lung Cancer News
- C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
- C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
- C4 Therapeutics appoints Reyno as Chief Medical Officer
- C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC